Inovio Pharmaceuticals (INO) Jumps 17% on Positive Day in Healthcare
Inovio Pharmaceuticals (INO) jumped 17% today. INO hasn’t released any press releases today, but late last week the Company announced positive interim Phase 1/2 results for INO-3107 for the treatment of recurrent respiratory papillomatosis. For more information on the trial update – see here: Press Release
Inovio also could have been positively affected by the market reacting to news that the U.S. is pushing for more COVID booster shots. Inovio has a potentical covid booster, INO-480, in it’s pipeline, in addition to eight other therapies treating ebola and prostate cancer.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from infectious diseases, cancer, and diseases associated with HPV. Our DNA medicines in development are delivered using our investigational proprietary smart device to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.
